A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.
LOXO-PIK-21001
Phase 1 other active
Quick answer
A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. for Advanced Breast Cancer and Other Solid Tumors is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Advanced Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active